CO2025010725A2 - Compuestos moduladores de receptores de dopamina d3/d2 - Google Patents
Compuestos moduladores de receptores de dopamina d3/d2Info
- Publication number
- CO2025010725A2 CO2025010725A2 CONC2025/0010725A CO2025010725A CO2025010725A2 CO 2025010725 A2 CO2025010725 A2 CO 2025010725A2 CO 2025010725 A CO2025010725 A CO 2025010725A CO 2025010725 A2 CO2025010725 A2 CO 2025010725A2
- Authority
- CO
- Colombia
- Prior art keywords
- dopamine
- modulating compounds
- receptor modulating
- formula
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363479530P | 2023-01-11 | 2023-01-11 | |
| PCT/IB2024/000026 WO2024150068A2 (en) | 2023-01-11 | 2024-01-10 | Dopamine d3/d2 receptor modulating compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2025010725A2 true CO2025010725A2 (es) | 2025-08-29 |
Family
ID=89573273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2025/0010725A CO2025010725A2 (es) | 2023-01-11 | 2025-08-05 | Compuestos moduladores de receptores de dopamina d3/d2 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12168007B1 (enExample) |
| EP (1) | EP4400495A1 (enExample) |
| JP (2) | JP7686096B2 (enExample) |
| CN (1) | CN120569367A (enExample) |
| AR (1) | AR131577A1 (enExample) |
| AU (1) | AU2024208533A1 (enExample) |
| CL (1) | CL2025002035A1 (enExample) |
| CO (1) | CO2025010725A2 (enExample) |
| GE (1) | GEAP202516807A (enExample) |
| IL (1) | IL321654A (enExample) |
| MX (1) | MX2025008101A (enExample) |
| TW (1) | TW202432139A (enExample) |
| WO (1) | WO2024150068A2 (enExample) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227534B1 (en) | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| EP1870405A1 (en) | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
| US8686009B2 (en) | 2009-06-25 | 2014-04-01 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds |
| WO2020156312A1 (zh) | 2019-01-30 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
| CN118772126A (zh) | 2019-10-29 | 2024-10-15 | 上海翰森生物医药科技有限公司 | 四元环类衍生物调节剂、其制备方法和应用 |
| WO2021088920A1 (zh) | 2019-11-05 | 2021-05-14 | 上海翰森生物医药科技有限公司 | 苯并噻吩类衍生物调节剂、其制备方法和应用 |
-
2024
- 2024-01-09 AR ARP240100045A patent/AR131577A1/es unknown
- 2024-01-10 EP EP24151077.5A patent/EP4400495A1/en active Pending
- 2024-01-10 US US18/409,478 patent/US12168007B1/en active Active
- 2024-01-10 TW TW113101017A patent/TW202432139A/zh unknown
- 2024-01-10 IL IL321654A patent/IL321654A/en unknown
- 2024-01-10 JP JP2024001696A patent/JP7686096B2/ja active Active
- 2024-01-10 GE GEAP202516807A patent/GEAP202516807A/en unknown
- 2024-01-10 CN CN202480007498.6A patent/CN120569367A/zh active Pending
- 2024-01-10 WO PCT/IB2024/000026 patent/WO2024150068A2/en not_active Ceased
- 2024-01-10 AU AU2024208533A patent/AU2024208533A1/en active Pending
- 2024-10-29 US US18/930,023 patent/US20250049786A1/en active Pending
-
2025
- 2025-05-19 JP JP2025083110A patent/JP2025122072A/ja active Pending
- 2025-07-09 CL CL2025002035A patent/CL2025002035A1/es unknown
- 2025-07-10 MX MX2025008101A patent/MX2025008101A/es unknown
- 2025-08-05 CO CONC2025/0010725A patent/CO2025010725A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7686096B2 (ja) | 2025-05-30 |
| KR20240112213A (ko) | 2024-07-18 |
| TW202432139A (zh) | 2024-08-16 |
| CN120569367A (zh) | 2025-08-29 |
| JP2024098972A (ja) | 2024-07-24 |
| JP2025122072A (ja) | 2025-08-20 |
| US12168007B1 (en) | 2024-12-17 |
| GEAP202516807A (en) | 2025-08-25 |
| US20250049786A1 (en) | 2025-02-13 |
| WO2024150068A3 (en) | 2024-08-22 |
| CL2025002035A1 (es) | 2025-10-03 |
| WO2024150068A2 (en) | 2024-07-18 |
| IL321654A (en) | 2025-08-01 |
| MX2025008101A (es) | 2025-08-01 |
| AU2024208533A1 (en) | 2025-07-10 |
| AR131577A1 (es) | 2025-04-09 |
| EP4400495A1 (en) | 2024-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38553A (es) | Inhibidores de cdk2 | |
| CO2017009891A2 (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| NI201900013A (es) | Inhibidor de piridopirimidinona cdk2/4/6 | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| UY30641A1 (es) | Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| DOP2006000169A (es) | Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| CO2020014677A2 (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
| ECSP15035530A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
| CL2009000445A1 (es) | Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion. | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| CO2021013166A2 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| ECSP088966A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| PA8589801A1 (es) | Aminoalcoxiindoles | |
| MX2021002260A (es) | Compuestos utiles como moduladores de la autofagia mediada por chaperonas. | |
| UY29197A1 (es) | Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos | |
| HN2011000404A (es) | Derivados de enfumafungina y composicion comprendiendo los mismos | |
| CU20190095A7 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| CO2025010725A2 (es) | Compuestos moduladores de receptores de dopamina d3/d2 | |
| CL2024001524A1 (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |